结直肠癌中的药物基因组学与遗传学

Pharmacogenomics and -genetics in colorectal cancer.

作者信息

Pohl Alexandra, Lurje Georg, Manegold Philipp C, Lenz Heinz-Josef

机构信息

Division of Medical Oncology, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA.

出版信息

Adv Drug Deliv Rev. 2009 May 20;61(5):375-80. doi: 10.1016/j.addr.2008.10.002. Epub 2008 Dec 3.

DOI:10.1016/j.addr.2008.10.002

PMID:19100300

Abstract

Despite recent progress in our knowledge about the development and therapy of colorectal cancer (CRC), it still remains one of the major cancer related deaths throughout the world. With the introduction of new cytotoxic and targeting agents a significant improvement in progression-free and overall survival has been achieved. However, a significant percentage (40-50%) of patients do not experience beneficial effects and suffer from severe toxicities. It will be critical to identify molecular markers, which may help to assess therapeutic response and outcome in CRC. Validation of predictive and prognostic molecular markers will enable oncologists to tailor patient specific treatment strategies for the individual patient according to the molecular profile of both the patient and their tumor. Individualized therapy will help to improve therapeutic efficacy and to minimize toxicities and therapeutic expenses.

摘要

尽管我们在结直肠癌（CRC）的发展和治疗方面的知识最近取得了进展，但它仍然是全球主要的癌症相关死亡原因之一。随着新的细胞毒性和靶向药物的引入，无进展生存期和总生存期有了显著改善。然而，相当比例（40-50%）的患者没有体验到有益效果，并且遭受严重毒性。识别分子标志物将至关重要，这可能有助于评估CRC的治疗反应和结果。预测性和预后性分子标志物的验证将使肿瘤学家能够根据患者及其肿瘤的分子特征为个体患者量身定制特定的治疗策略。个体化治疗将有助于提高治疗效果，并将毒性和治疗费用降至最低。